

*JP*

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 3, 2006

Signature: Christine M. Grace

(Christine M. Grace)

Docket No.: VASG-P01-002  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Krasnoperov et al.

Application No.: 10/800,350

Filed: March 12, 2004

Art Unit: 1642

For: POLYPEPTIDE COMPOUNDS FOR  
INHIBITING ANGIOGENESIS AND  
TUMOR GROWTH

Examiner: S. E. Aeder


**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicants have become aware of the following documents, cited in an International Search Report issued July 3, 2006, during the prosecution of international application no. PCT/US2005/034179, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the International Search Report and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.



Application No.: 10/800,350

Docket No.: VASG-P01-002


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. VASG-P01-002.

Dated: August 3, 2006

Respectfully submitted,

By   
Z. Angela Guo

Registration No.: 54,144  
FISH & NEAVE IP GROUP, ROPES & GRAY  
LLP  
One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/800,350	
			Filing Date	March 12, 2004	
			First Named Inventor	Valery Krasnoperov	
			Art Unit	1642	
			Examiner Name	S. E. Aeder	
Sheet	1	of	1	Attorney Docket Number	VASG-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO 04/080425	09-23-2004	Vasgene Therapeutics, Inc.		
	BB	WO 04/024773	03-25-2004	The Queen Elizabeth Hospital		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CA	Berclaz Gilles et al., "Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast," <u>Oncology Reports</u> , 9(5):985-989 (2002).		
	CB	Caplen, N.J., "RNAi as a Gene Therapy Approach," <u>Expert Opin. on Biol. Therapy</u> , 3(4):575-586 (2003).		
	CC	Cromer et al., "Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis," <u>Oncogene</u> , Basingstoke, Hants, GB, 23(14):2484-2498 (2004).		
	CD	Santa Cruz, "EphB4 (N-19): sc-7285," <u>Product Catalog of Santa Cruz Biotechnology</u> (1999).		
	CE	Sinha et al., "Expression of EphB4 in head and neck squamous cell carcinoma," <u>Bar, Nose, and Throat Journal</u> , 82(11):866, 869-870, 887 (2003).		
	CF	Takai et al., "Expression of receptor tyrosine kinase EphB4 and its ligand Ephrin-B2 is associated with malignant potential in endometrial cancer," <u>Oncology Reports</u> , National Hellenic Research Foundation, 8(3):567-573 (2001).		
	CG	Yang et al., "Gene Targets of Antisense Therapies in Breast Cancer," <u>Expert Opin. on Therapeutic Targets</u> , 6(3):375-385 (2002).		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--